IRB #

STUDY00018386

Title

Monoclonal antibody-based sequential therapy for deep remission in multiple myeloma – MASTER trial

Principal Investigator

Eva Medvedova

Study Purpose

This research study will determine the frequency of minimal residual disease (MRD) after prescribed course of standard drug treatment, combined with daratumumab in participants with newly diagnosed multiple myeloma. Minimal residual disease is multiple myeloma cells below the level of that which we can detect with available technology today.

Medical Condition(s)

Newly diagnosed multiple myeloma

Eligibility Criteria

- Men and women at least 18 years of age who have been diagnosed with multiple myeloma
- No prior treatment for your multiple myeloma

Age Range

18 - 99

Healthy Volunteers Needed

No

Duration of Participation

You will receive the study drugs for 14 to 22 months, depending on your response and MRD. After you finish the study drugs, the investigator will continue to watch you for side effects and follow your condition until you start a new treatment regimen.

Minors Included

No

Contact

Clinical Trials Information Line
Phone: 503-494-1080
Email: trials@ohsu.edu

Sponsor

University of Alabama at Birmingham Comprehensive Cancer Center

Recruitment End

06/01/2022

Compensation Provided

No


Go Back